Screening for Chlamydia trachomatis in secondary schools, family planning and occupational health centres in Luxembourg
- 1Microbiology, National Health Laboratory, Luxembourg
- 2Division of School Health, Health Directorate, Luxembourg
- 3Multisectorial Health at Work Services, Luxembourg
- 4Family Planning, Luxembourg
- Correspondence to Dr J Mossong, Laboratoire National de Santé, PO Box 1102, L-1011 Luxembourg;
- Accepted 13 June 2009
- Published Online First 1 July 2009
Background: We conducted a prospective pilot screening study in three settings in Luxembourg where routine urine testing is carried out independently for other purposes with a short sexual behaviour questionnaire to estimate prevalence and determine risk factors of urogenital Chlamydia trachomatis infection.
Methods: Screening was offered to sexually active volunteer participants aged less than 25 years in three settings: i) women in three family planning centres (FPC), ii) young women and men in 29 secondary schools and iii) women and men in an occupational health centre (OHC) for newly recruited employees and workers. First catch urine samples were tested using the COBAS Amplicor and an in-house assay. Multiple logistic regression was performed to analyse risk factors.
Results: Overall prevalence among 4141 participants was 7.7% (95% CI 6.3 to 9.2) in FPCs, 1.9% (95% CI 1.2 to 2.8) in secondary schools and 4.5% (95% CI 3.5 to 5.6) in the OHC. Depending on the setting, identified risk factors included being 18–22 years old, female sex, having three or more sexual partners in the past year and inconsistent condom use
Conclusion: Screening is feasible in the three settings, but the prevalence of C trachomatis infection among men and women is highest in age groups that have left secondary school. Family planning centres were the setting with the highest C trachomatis prevalence and the only setting in our study able to provide case management, follow-up and repeat testing.
Funding The study was funded by the Centre de Recherche Public-Santé and we gratefully acknowledge Pfizer for providing free azithromycin treatment to study participants.
Competing interests None.
Ethics approval Obtained by the national research ethics committee.
Contributors JM designed the study, conducted the data analysis and wrote the manuscript; MM organised screening at the secondary schools and reviewed the manuscript; NM organised the screening at the occupational health centre and reviewed the manuscript; CM organised the screening at the family planning centres and reviewed the manuscript; FD and FS designed the in-house test, conducted the laboratory testing and reviewed the manuscript.
Provenance and peer review Not commissioned; externally peer reviewed.